一項(xiàng)最新研究證實(shí)，簡(jiǎn)單的血液檢測(cè)能夠分析患者的基因，能夠準(zhǔn)確測(cè)定心臟移植排斥情況。

AlloMap檢測(cè)使用實(shí)時(shí)定量PCR(PCR)和運(yùn)算法則來(lái)分析患者的基因表達(dá)。該檢測(cè)檢測(cè)出排斥情況，意味著較低的檢測(cè)成本就能夠十分可靠地鑒別出患者是否對(duì)心臟移植不會(huì)排斥。該檢測(cè)最主要優(yōu)點(diǎn)是鑒別出低風(fēng)險(xiǎn)患者，這些患者能夠使用非創(chuàng)傷性方法進(jìn)行監(jiān)測(cè)和處理；以及那些需要積極使用強(qiáng)效免疫藥物的患者，這些藥物常常有嚴(yán)重的副作用。

Gene Expression Test Rules Out Transplant Rejection
 
A new study confirms that a simple blood test that analyzes a patient's genes can accurately detect the absence of heart transplant rejection.

The AlloMap test uses real-time polymerase chain reaction (PCR) and an algorithm to analyze the patient's gene expression. The test rules out rejection, meaning that a low test score very reliably identifies the transplant patient who is not rejecting the transplanted heart. The primary advantage of the test is to identify low-risk patients who can be monitored and managed using noninvasive methods and who may benefit from being more aggressively weaned off intensive immunosuppressive regimens that are associated with serious side effects.